Levity Shows Confidence Ahead of Earnings Report: What Caused the 6% Surge in Stock Price?

Revvity Inc. (NASDAQ: RVTY) shares surged 6.08% to $110.18 on the New York Stock Exchange on January 13. The company’s market capitalization climbed by about $890 million (roughly KRW 1.17 trillion) in a single day. Trading volume topped 1.37 million shares, exceeding its 50-day average. Buying interest in both after-hours and regular trading sessions was widely attributed to investors’ reaction to Revvity’s upwardly revised 2025 guidance.

The immediate catalyst was an 8-K filing and accompanying update to the company’s outlook. Revvity said its adjusted earnings per share for 2025 will surpass the prior upper range of $4.90–$5.00. It also provided preliminary fourth-quarter revenue of approximately $772 million, above the Wall Street consensus of about $760 million, and forecast full-year sales near $2.855 billion, exceeding market expectations. This “sneak preview” ahead of management’s presentation at the J.P. Morgan Healthcare Conference on January 13 and the formal earnings call set for February 2 helped fuel bullish sentiment among investors.

Headquartered in Waltham, Massachusetts, Revvity is a health-science solutions company serving pharmaceutical and biotech firms, diagnostic labs, academic institutions, and government agencies. It offers a fully integrated workflow—from multi-omics-based biomarker discovery to imaging, screening, detection, diagnostic instruments and software, and informatics solutions—supporting customers through research, development, diagnostics and treatment. In 2024, Revvity generated over $2.7 billion in revenue and built a global network spanning more than 160 countries with approximately 11,000 employees.

Despite the recent rally, Revvity’s stock remains roughly 20% below its 52-week high, reflecting a sector-wide valuation reset among diagnostic and research-equipment companies triggered by economic slowdown concerns and reduced R&D budgets. Investors are now closely watching whether the company’s raised 2025 guidance, its February earnings release, and the mid- to long-term strategy unveiled at the healthcare conference will serve as a catalyst for a sustained re-rating of the shares.